Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Triangle Pharmaceuticals Inc.

Division of Gilead Sciences Inc.
www.tripharm.com

Latest From Triangle Pharmaceuticals Inc.

Gilead Cites 'More Sophisticated' Process As Pressure For A Major Deal Increases

CEO John Milligan offered few details about Gilead's deal strategy during an investor conference last week, but analysts think internal pressure for a major deal is beginning to equal the external sentiment, including an analyst who sees Incyte as a likely target, but not a quick fix for Gilead's declining HCV drug sales.

Commercial Business Strategies

Where There's A Cure There's Controversy: Raymond Schinazi's Story

It is thought that more than 94% of HIV-infected individuals in the US on combination therapy take at least one of the drugs Raymond F Schinazi has invented. Most latterly associated with hepatitis C cure sofosbuvir, Schinazi tell Jo Shorthouse why he has no intentions of stopping any time soon.

Infectious Diseases Pricing Debate

Ocera Forwards Liver Disease Drug After Reverse Merger With Tranzyme

Ocera went public by completing a reverse merger with the failing biotech Tranzyme, then completed a $20 million PIPE financing that positions it to begin a Phase IIb trial studying its lead drug for a rare liver disease.

BioPharmaceutical Business Strategies

Record-Setting Deal For Pharmasset Expected To Boost Value Of Other HCV Biotechs

The $11 billion Gilead plans to pay for Pharmasset dwarfs any prior deal for a clinical-stage biotech, and should be good news for other biotechs with hepatitis C candidates, like Inhibitex, Achillion and Idenix.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Gilead Sciences Inc.
  • Senior Management
  • Daniel G Welch, Chmn. & CEO
    Robert Amundsen, Jr., CFO
    Phillip Furman, PhD, VP, Research & CSO
    Chris A Rallis, Pres. & COO
  • Contact Info
  • Triangle Pharmaceuticals Inc.
    Phone: (919) 493-5980
    4611 University Dr.
    P.O. Box 50530 Durham, NC 27707-0530
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register